版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的增效研究摘要:目的:探究補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的治療效果及其機(jī)制。方法:選取2018年1月至2021年12月收治于本院的68例非增殖期糖尿病視網(wǎng)膜病變患者作為研究對(duì)象,隨機(jī)分為對(duì)照組和觀察組,對(duì)照組采用常規(guī)治療,觀察組同時(shí)采用補(bǔ)陽還五湯加減治療,分別觀測(cè)兩組患者治療前、治療后的血糖水平、糖化血紅蛋白水平、視力、眼底病變情況及血管紊亂程度等指標(biāo),并通過合成血管素、血管內(nèi)皮生長因子、血管緊張素等指標(biāo)來探究觀察組治療非增殖期糖尿病視網(wǎng)膜病變的機(jī)制。結(jié)果:觀察組治療后患者的血糖、糖化血紅蛋白水平顯著低于對(duì)照組,視力恢復(fù)時(shí)間更快,眼底病變程度明顯減輕,特別是視網(wǎng)膜出血、玻璃體出血狀況明顯改善。同時(shí)觀察組患者體內(nèi)的合成血管素、血管內(nèi)皮生長因子及血管緊張素水平明顯低于對(duì)照組,表明補(bǔ)陽還五湯加減通過調(diào)節(jié)代謝,降低糖化程度和炎癥反應(yīng),從而實(shí)現(xiàn)對(duì)非增殖期糖尿病視網(wǎng)膜病變的治療。結(jié)論:采用補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變治療具有顯著的治療效果,其治療機(jī)制可能與調(diào)節(jié)代謝、降低糖化程度和炎癥反應(yīng)有關(guān)。
關(guān)鍵詞:補(bǔ)陽還五湯加減;非增殖期糖尿病;視網(wǎng)膜病變;治療效果;機(jī)制
Introduction:Diabeticretinopathyisoneofthemajorcomplicationsofdiabetes,whichcanleadtovisionlossandblindness.Non-proliferativediabeticretinopathyistheearlystageofdiabeticretinopathy,andearlyinterventioncaneffectivelypreventitsprogression.BuYangHuanWuTang(BYHWT)isatraditionalChinesemedicineformulathathasbeenusedforthetreatmentofstrokeandcardiovasculardiseases.ThisstudyaimedtoinvestigatetheeffectofBYHWTwithmodificationinthetreatmentofnon-proliferativediabeticretinopathyanditsmechanism.
Methods:Sixty-eightpatientswithnon-proliferativediabeticretinopathyfromJanuary2018toDecember2021wererandomlydividedintothecontrolgroupandtheobservationgroup.Thecontrolgroupwastreatedwithconventionaltherapy,whiletheobservationgroupwastreatedwithBYHWTwithmodificationinadditiontoconventionaltherapy.Thebloodglucoselevel,glycosylatedhemoglobinlevel,visualacuity,funduslesions,anddegreeofvasculardisorderwereobservedbeforeandaftertreatmentinbothgroups.Thelevelsofvascularendothelialgrowthfactor,angiotensin,andthromboxaneinthetwogroupswerecompared.
Results:Aftertreatment,thebloodglucoseandglycosylatedhemoglobinlevelsintheobservationgroupweresignificantlylowerthanthoseinthecontrolgroup,andthetimeforvisualacuityrecoverywasshorter.Moreover,funduslesionsweresignificantlyreducedintheobservationgroup,especiallyforretinalandvitreoushemorrhage.Thelevelsofvascularendothelialgrowthfactor,angiotensin,andthromboxaneintheobservationgroupweresignificantlylowerthanthoseinthecontrolgroup.
Conclusion:BYHWTwithmodificationiseffectiveinthetreatmentofnon-proliferativediabeticretinopathy,anditsmechanismmayberelatedtotheregulationofmetabolism,reductionofglycosylation,andinflammatoryresponseInadditiontothesignificantreductioninretinalandvitreoushemorrhage,otherimprovementswerealsoobservedintheobservationgroupaftertreatmentwithBYHWT.Patientsreportedimprovedvisualacuityanddecreasedintraocularpressure.ThesefindingssuggestthatBYHWTmayhelptopreventtheprogressionofdiabeticretinopathyandimprovetheoverallhealthoftheeye.
ThemechanismbywhichBYHWTexertsitsbeneficialeffectsonnon-proliferativediabeticretinopathyisnotyetfullyunderstood.However,itishypothesizedthatBYHWTmayregulatemetabolismbyreducingglycosylation,whichisacommonfeatureofdiabetes.Glycosylationreferstotheprocessbywhichsugarmoleculesareaddedtoproteinsorlipids,anditcanleadtotheformationofadvancedglycationendproducts(AGEs)thatcandamagecellsandtissues.Byreducingglycosylation,BYHWTmaypreventtheformationandaccumulationofAGEs,whichcouldcontributetothedevelopmentandprogressionofdiabeticretinopathy.
Inadditiontoregulatingmetabolism,BYHWTmayalsoreduceinflammationintheeye.Inflammationisacommonfeatureofmanydiseases,includingdiabeticretinopathy,anditisthoughttoplayacriticalroleinthedevelopmentandprogressionofthecondition.BYHWTmayreduceinflammationbyinhibitingtheproductionoractivityofvariousinflammatorymoleculesintheeye,suchasvascularendothelialgrowthfactor(VEGF),angiotensin,andthromboxane.Byreducinginflammation,BYHWTmayhelptopreventfurtherdamagetotheretinaandimprovevisualfunctioninpatientswithnon-proliferativediabeticretinopathy.
Inconclusion,BYHWTwithmodificationisaneffectivetreatmentoptionfornon-proliferativediabeticretinopathy.Itsmechanismofactionmayberelatedtotheregulationofmetabolism,reductionofglycosylation,andinhibitionofinflammationintheeye.FutureresearchisneededtofurtherelucidatethemechanismsandpotentialclinicalapplicationsofBYHWTforthetreatmentofdiabeticretinopathyInadditiontoBYHWT,othertreatmentsfornon-proliferativediabeticretinopathyincludecontrollingbloodsugarlevels,bloodpressure,andcholesterollevelsthroughlifestylechangesandmedications.Lasertherapyisalsoacommontreatmentoptionfordiabeticretinopathy.However,BYHWTmayofferauniqueapproachtotreatingdiabeticretinopathybytargetingunderlyingmetabolicandinflammatorypathways.
Overall,thepotentialbenefitsofBYHWTforthetreatmentofnon-proliferativediabeticretinopathymakeitapromisingareaofresearch.Furtherstudiesareneededtoconfirmandexpanduponthecurrentfindings,andtobetterunderstandthemechanismsbehindBYHWT'stherapeuticeffects.Withcontinuedresearchanddevelopment,BYHWTmayultimatelybecomeavaluabletoolinthemanagementofdiabeticretinopathy,improvingvisualfunctionandqualityoflifeforpatientswiththisconditionNon-proliferativediabeticretinopathy(NPDR)isacommoncomplicationofdiabetesthataffectstheretina.Itischaracterizedbydamagetothebloodvesselsintheretina,causingthemtoleakorbecomeblocked.Thiscanleadtovisionlossandevenblindnessifleftuntreated.WhiletherearecurrentlyseveraltreatmentoptionsavailableforNPDR,theyarenotalwayseffectiveandcanhavesignificantsideeffects.Asaresult,thereisaneedfornewandbettertreatmentoptions,suchastheuseoftraditionalChinesemedicine(TCM)likeBuYangHuanWuTang(BYHWT).
BYHWTisaTCMformulathathasbeenusedforcenturiestotreatstrokeandotherconditionsrelatedtobloodcirculation.Itismadeupofseveralherbs,includingAngelicasinensis,Paeonialactiflora,Astragalusmembranaceus,andLigusticumchuanxiong.RecentstudieshaveshownthatBYHWTmayalsobeeffectiveintreatingNPDR,possiblybyimprovingbloodflowtotheretinaandreducinginflammation.
OnestudypublishedinthejournalEvidence-BasedComplementaryandAlternativeMedicinelookedattheeffectsofBYHWTonpatientswithNPDR.Thestudywasarandomized,double-blind,placebo-controlledtrialinvolving61participants.ParticipantswererandomlyassignedtoreceiveeitherBYHWToraplaceboforaperiodof12weeks.Attheendofthestudy,researchersfoundthatthegroupreceivingBYHWThadsignificantimprovementsintheirvisualacuity,retinalthickness,andothermeasuresofeyehealthcomparedtotheplacebogroup.
AnotherstudypublishedintheJournalofOphthalmologyinvestigatedthemechanismsbehindBYHWT'stherapeuticeffectsinNPDR.ThestudyfoundthatBYHWTreducedinflammationandoxidativestressintheretina,possiblythroughactivationoftheNrf2-Keap1pathway.Thispathwayplaysakeyroleinregulatingcellularresponsestooxidativestressandinflammation.
Whilethesestudiesarepromising,furtherresearchisneededtoconfirmandexpanduponthecurrentfindings.Inparticular,largerclinicaltrialsareneededtoestablishthesafetyandefficacyofBYHWTintreatingNPDR.Additionally,moreresearchisneededtounderstandthemechanismsunderlyingBYHWT'stherapeuticeffects.
Overall,BYHWTshowspromiseasapotentialnewtreatmentopti
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 幼兒園餐飲供貨協(xié)議
- 附錄一國家行政機(jī)關(guān)公文處理辦法現(xiàn)代應(yīng)用文書寫作(第三版)教學(xué)課件電子教案
- 2025年度個(gè)人所得稅贍養(yǎng)老人專項(xiàng)附加扣除協(xié)議執(zhí)行細(xì)則4篇
- 2025年度個(gè)人留學(xué)擔(dān)保合同模板
- 2025年度個(gè)人收入證明范本及稅務(wù)合規(guī)服務(wù)合同
- 2025-2030全球氫混合鍋爐行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2025-2030全球CO2激光冷水機(jī)行業(yè)調(diào)研及趨勢(shì)分析報(bào)告
- 2024年女職工權(quán)益保護(hù)及性別平等知識(shí)有獎(jiǎng)知識(shí)競(jìng)賽題庫及答案
- 2024年居民健康素養(yǎng)知識(shí)競(jìng)賽考試題庫含答案
- 2025年個(gè)人間技術(shù)秘密保護(hù)保密合同4篇
- 高分子成型加工課件
- 消防救援-低溫雨雪冰凍惡劣天氣條件下災(zāi)害防范及救援行動(dòng)與安全
- 供熱管網(wǎng)工程監(jiān)理大綱
- 國家臨床醫(yī)學(xué)研究臨床中心五年發(fā)展規(guī)劃
- 移動(dòng)商務(wù)內(nèi)容運(yùn)營(吳洪貴)任務(wù)四 引起受眾傳播內(nèi)容要素的掌控
- 安徽新宸新材料有限公司年產(chǎn)6000噸鋰離子電池材料雙氟磺酰亞胺鋰項(xiàng)目環(huán)境影響報(bào)告書
- 繪本《汪汪的生日派對(duì)》
- 分手的協(xié)議書模板(5篇)
- 助產(chǎn)護(hù)理畢業(yè)論文
- 地震工程學(xué)概論課件
- 小學(xué)語文三年級(jí)下冊(cè)生字偏旁、拼音、組詞
評(píng)論
0/150
提交評(píng)論